Rezvilutamide versus enzalutamide for low-volume metastatic hormone-sensitive prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase III comparison gives eligible men either rezvilutamide tablets or enzalutamide capsules while they continue standard androgen-deprivation therapy (ADT). The study compares disease control and safety between the two oral androgen-receptor inhibitors in patients with low-volume metastatic hormone-sensitive prostate cancer and ECOG performance status 0–1. Participants must have prostate adenocarcinoma without neuroendocrine or small cell features and meet predefined organ function and contraceptive requirements. The trial is sponsored by Jiangsu HengRui Medicine and is being conducted at The First Medical Center of the PLA General Hospital in Beijing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily participates in this clinical trial, with an understanding of the study procedures and signed informed consent;
2. Age ≥ 18 years;
3. Histologically or cytologically confirmed prostate adenocarcinoma without evidence of neuroendocrine differentiation or small cell features;
4. Metastatic hormone sensitive prostate cancer;
5. ECOG PS: 0-1;
6. Planned to receive and maintain ADT during the study period;
7. Adequate hepatic, renal, heart, and hematological functions;
8. Determined by the investigator to be able to comply with the study protocol;
9. Fertile subjects must use effective contraception or abstain from sexual activity and sperm donation until 3 months after last exposure to rezvilutamide or enzalutamide. Subjects must use condoms plus an additional effective contraceptive method during sexual activity with a fertile female partner throughout treatment and for 3 months post-treatment.

Exclusion Criteria:

1. Prior treatment with ADT, chemotherapy, surgery, external-beam radiotherapy, brachytherapy, radiopharmaceuticals, or investigational local therapy for metastatic prostate cancer, except as specifically allowed by the protocol;
2. Previous use of second-generation androgen receptor antagonists, ketoconazole, abiraterone acetate, or other investigational drugs inhibiting androgen synthesis for prostate cancer treatment; or plans to use any second-generation androgen receptor antagonist other than the study drug during the study treatment period;
3. Total PSA has decreased to undetectable levels at baseline;
4. Have participated in an interventional clinical trial or been treated with the following drugs in the past 4 weeks before randomization: 5-alpha reductase inhibitors, estrogen, progestin, and herbal products known to decrease PSA levels;
5. Planned to initiate any other anti-tumor therapies during the study;
6. Known history of hypersensitivity to rezvilutamide, enzalutamide, or any of their components;
7. Unable to swallow, chronic diarrhea or intestinal obstruction, or the presence of a variety of other factors that affect drug use and absorption;
8. History of seizure or certain conditions that may predispose to seizure;
9. Presence of clinically significant cardiovascular diseases within 6 months prior to randomization;
10. Any other malignancy within 5 years prior to randomization (except as specifically allowed by the protocol);
11. Active HBV or HCV infection;
12. History of immunodeficiency (including HIV-positive status, other acquired or congenital immunodeficiency disorders) or organ transplantation;
13. Any concomitant condition that, in the opinion of the investigator, would seriously jeopardize patient safety, confound study findings, or compromise the patient's ability to complete the study (e.g., hypertension inadequately controlled despite medication, severe diabetes, neurologic or psychiatric disorders, etc.) or any other circumstance.

Where it's running

• The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Daomin Hu
• Email: hudaomin@aidiyan.com
• Phone: +86-0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Saruparib plus physician’s ARPI choice vs placebo in men with metastatic hormone-sensitive prostate cancer previously treated with docetaxel or Lu-PSMA

  This study tests whether adding saruparib to a physician’s choice of ARPI helps men with metastatic hormone-sensitive prostate cancer who have already had docetaxel or Lu-PSMA therapy and no progression, compared with placebo plus ARPI.

  Recruiting at 6 sites Phase 3 AstraZeneca · Hot Springs, Arkansas and 209 other locations · NCT07711002

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• How darolutamide with hormone therapy works for advanced prostate cancer in German practice

  This observational study looks at how well darolutamide added to hormone therapy works for German men with metastatic hormone-sensitive prostate cancer who are already starting this combination in routine care.

  Recruiting Bayer · Locations · NCT07395804

• PSA‑triggered intermittent relugolix plus ARPI for metastatic hormone‑sensitive prostate cancer

  This trial will test whether taking relugolix with an androgen receptor pathway inhibitor on an intermittent schedule based on PSA levels works for men with metastatic hormone‑sensitive prostate cancer who achieve a strong PSA response.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT07216248

• Tulmimetostat with darolutamide or abiraterone for metastatic hormone-sensitive prostate cancer

  This trial will test whether adding tulmimetostat to darolutamide or abiraterone helps men with metastatic hormone-sensitive prostate cancer control their cancer better.

  Recruiting at 30 sites Phase 1/2 Novartis · Birmingham, Alabama and 30 other locations · NCT07190300

• Adding xaluritamig to androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer

  This trial tests whether adding xaluritamig to darolutamide or abiraterone is safe and tolerable for men with high-volume metastatic hormone-sensitive prostate cancer who have recently started hormone therapy.

  Recruiting at 16 sites Phase 1 Amgen · San Francisco, California and 15 other locations · NCT07140900

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.